Patents by Inventor SANTOSH S. KULKARNI

SANTOSH S. KULKARNI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230250073
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: January 12, 2023
    Publication date: August 10, 2023
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 11683852
    Abstract: Techniques are disclosed for determining one or more radio resource management (RRM) input parameters. The one or more RRM input parameters are determined based on a line of sight (LOS) estimate between two wireless stations (STAs). A plurality of RRM values are generated based on the one or more RRM input parameters. A wireless connection is established between a first wireless access point (AP) and a first STA using the RRM values.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: June 20, 2023
    Assignee: Cisco Technology, Inc.
    Inventors: Pooya Monajemi, Santosh B. Kulkarni, Benjamin J. Cizdziel, Vishal S. Desai, Young Il Choi
  • Publication number: 20230189064
    Abstract: Techniques are provided for optimizing performance of a multi-link device (MLD). In one embodiment, a controller receives information about a filter response for a first multi-link device (MLD, determines, based on the information about the filter response, a filtering transitional region of the first MLD indicating a range of frequencies where there is energy leakage due to the first MLD device operating in a simultaneous transmission and reception (STR) mode, determines cost metrics for a plurality of channels by identifying a STR and non-STR (NSTR) ratio for each of the plurality of channels, and assigns, based on the filtering transitional region and the cost metrics, a first radio of an access point (AP) to one of the plurality of channels to enable the first MLD to operate in the STR mode when communicating with the first radio.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 15, 2023
    Inventors: Pooya MONAJEMI, Vishal S. DESAI, Malcolm M. SMITH, Santosh B. KULKARNI, Young Il CHOI
  • Publication number: 20230178890
    Abstract: Flexible radio assignment with beamsteering antennas is provided by controlling a plurality of Access Points (APs) including steerable antennas to each transmit a first plurality of discovery frames at a first beamwidth; controlling the plurality of APs to steer the steerable antennas at a second beamwidth, less than the first beamwidth, to a plurality of steering angles; controlling the plurality of APs to each transmit a second plurality of discovery frames at each steering angle of the plurality of steering angles; determining an overlap in radio coverage among the plurality of APs based on the first plurality and the second plurality of discovery frames; and identifying redundant radios based on the overlap in radio coverage; and reassigning the redundant radios from use for client transmissions to a secondary role.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 8, 2023
    Inventors: Santosh B. KULKARNI, Vishal S. DESAI, Pooya MONAJEMI, Young Il CHOI
  • Publication number: 20230158024
    Abstract: One embodiment of the invention is a compound represented by Formula I: or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 25, 2023
    Inventors: Santosh S. Kulkarni, Bharat Lagu, Xinyuan Wu
  • Publication number: 20230120169
    Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Dawn V. TORONTO, David Malcolm CROWE
  • Patent number: 11612599
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 28, 2023
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 11603359
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: March 14, 2023
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 11591327
    Abstract: The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and, in particular, as glycosidase inhibitors.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: February 28, 2023
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri, Dawn V. Toronto, David Malcolm Crowe
  • Publication number: 20230049950
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: February 15, 2022
    Publication date: February 16, 2023
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Patent number: 11572350
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: February 7, 2023
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Publication number: 20230021684
    Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
    Type: Application
    Filed: May 13, 2022
    Publication date: January 26, 2023
    Inventors: Gerard M. MCGEEHAN, William H. MILLER, Nicholas Paul CAMP, Salvacion CACATIAN, Santosh S. KULKARNI, Swapan Kumar SAMANTA, Virsinha Venkat REDDY
  • Publication number: 20230025807
    Abstract: The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).
    Type: Application
    Filed: October 29, 2020
    Publication date: January 26, 2023
    Inventors: Santosh S. Kulkarni, Bharat Lagu, Xinyuan Wu
  • Publication number: 20220411440
    Abstract: The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 29, 2022
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20220380358
    Abstract: Compounds of formula (I?), wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R??, m and n have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 1, 2022
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI, Grant Wishart, Paul RAKESH
  • Patent number: 11458140
    Abstract: Compounds of formula (I), wherein A, R, W1, W2, W3, W4, W5, W6, L, Q, Rx and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: October 4, 2022
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 11377429
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: July 5, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Publication number: 20220177470
    Abstract: Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 9, 2022
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • Publication number: 20220162176
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Application
    Filed: February 10, 2022
    Publication date: May 26, 2022
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Publication number: 20220143042
    Abstract: This application pertains to compounds of formula (I) wherein A, Z, E, R1, R2, m and n have the meaning according to the claims, and the compounds can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: February 21, 2020
    Publication date: May 12, 2022
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Paul RAKESH